Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Mizue Terai"'
Development and optimization of orthotopic liver metastasis xenograft mouse models in uveal melanoma
Autor:
Bao Quoc Lam, Takahito Sugase, Meggie Danielson, Mizue Terai, Andrew E. Aplin, Takami Sato, J. Silvio Gutkind
Publikováno v:
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-14 (2020)
Journal of Translational Medicine
Journal of Translational Medicine
Background Patients with metastatic uveal melanoma (MUM) in the liver usually die within 1 year. The development of new treatments for MUM has been limited by the lack of diverse MUM cell lines and appropriate animal models. We previously reported th
A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis
Autor:
Misung Yi, Inna Chervoneva, David J. Eschelman, Takami Sato, P. Rani Anne, Carin F. Gonsalves, Robert D. Adamo, Marlana Orloff, Anthony N. Hage, Mizue Terai
Publikováno v:
Radiology
BACKGROUND: Overall survival (OS) for patients with uveal melanoma (UM) hepatic metastases is extremely poor. Therefore, stabilization of hepatic metastases is essential to prolonging OS. PURPOSE: To assess the safety and effectiveness of radioemboli
Autor:
Andrew E. Aplin, Hanyin Cheng, Mizue Terai, Takami Sato, Masahiro Ohara, Ken Kageyama, Kengo Saito
Publikováno v:
Cancers, Vol 13, Iss 1104, p 1104 (2021)
Cancers
Volume 13
Issue 5
Cancers
Volume 13
Issue 5
Uveal melanoma (UM) is the most common cancer of the eye in adults. Up to 50% of UM patients subsequently develop metastases, especially in the liver. It has been reported that the retinoblastoma (RB) pathway is deregulated in more than 90% of UM des
Autor:
Lihong Zhang, Mizue Terai, Eduardo F. Farias, Julio A. Aguirre-Ghiso, Clinita E. Randolph, Naiming Zhou, Takami Sato, Timothy J. Purwin, Philip B. Wedegaertner, Andrew E. Aplin, Gregory G. Tall, Shihua Wu, Dougan McGrath, Thomas H. Charpentier, Dominic Lapadula, Jeffrey L. Benovic
Publikováno v:
Molecular Cancer Research. 17:963-973
Uveal melanoma is the most common intraocular tumor in adults and often metastasizes to the liver, leaving patients with few options. Recurrent activating mutations in the G proteins, Gαq and Gα11, are observed in approximately 93% of all uveal mel
Autor:
Mital Shah, Takami Sato, Bharat Awsare, Rajiv A. Kabadi, Mizue Terai, Gautam George, Gregary D. Marhefka
Publikováno v:
Tex Heart Inst J
Locoregional cytokine treatment, or immunoembolization, is an experimental targeted therapy for uveal melanoma metastatic to the liver. Unlike systemic cytokine treatments that have been associated with substantial toxicity, this method of drug deliv
Autor:
Bao Lam, Eric Londin, Takami Sato, Emma O. Link, Ankit K. Rochani, Gagan Kaushal, Alok Bhushan, Mizue Terai, Marlana Orloff
Publikováno v:
Cancers
Volume 12
Issue 2
Cancers, Vol 12, Iss 2, p 405 (2020)
Volume 12
Issue 2
Cancers, Vol 12, Iss 2, p 405 (2020)
Uveal melanoma (UM) is the most common primary eye malignancy in adults and up to 50% of patients subsequently develop systemic metastasis. Metastatic uveal melanoma (MUM) is highly resistant to immunotherapy. One of the mechanisms for resistance wou
Autor:
Michael J. Guarino, Min Xiao, Giorgos C. Karakousis, Michael A. Davies, Andrea Watters, Ensar Halilovic, Gao Zhang, Alexander Roesch, Lauren E. Haydu, Giordano Caponigro, Keith T. Flaherty, Clemens Krepler, Katrin Sproesser, Gordon B. Mills, Sébastien Jeay, Andrew E. Aplin, Lynn M. Schuchter, Nicholas J. Petrelli, Joseph J. Bennett, Adina Vultur, David E. Elder, Meenhard Herlyn, Ravi K. Amaravadi, Michael Feldman, Xiangfan Yin, Melissa Wilson, Tara C. Gangadhar, Rakesh Kumar, Michela Perego, Carol L. Shields, Katherine L. Nathanson, Marilda Beqiri, Jennifer A. Wargo, Matthias Ocker, Takami Sato, Qin Liu, Michal Barzily-Rokni, Batool Shannan, Ioannis N. Anastopoulos, Dennie T. Frederick, Bradley Garman, Xiaowei Xu, Dave S.B. Hoon, Mizue Terai, Randall W Ryan, Yiling Lu, Bradley Wubbenhorst, Patricia Brafford, Matthew B. Boxer, Annette O. Walter, Wei Xu, Jens Wuerthner, Steve Angus, David B. Darr
Publikováno v:
Cell Reports, Vol 21, Iss 7, Pp 1953-1967 (2017)
Summary: Therapy of advanced melanoma is changing dramatically. Following mutational and biological subclassification of this heterogeneous cancer, several targeted and immune therapies were approved and increased survival significantly. To facilitat
Autor:
Mizue Terai, Paolo Fortina, Shinji Ozaki, Ken Kageyama, Andrew E. Aplin, Takami Sato, Kengo Saito, Masahiro Ohara, Michael J. Mastrangelo
Publikováno v:
Journal of Translational Medicine, Vol 15, Iss 1, Pp 1-19 (2017)
Journal of Translational Medicine
Journal of Translational Medicine
Background Metastatic uveal melanoma is a highly fatal disease; most patients die from their hepatic metastasis within 1 year. A major drawback in the development of new treatments for metastatic uveal melanoma is the difficulty in obtaining appropri
Autor:
Connie Liao, Andrew E. Aplin, Takami Sato, Vivian Chua, Mizue Terai, Timothy J. Purwin, Ken Kageyama, Michael A. Davies, Hanyin Cheng
Publikováno v:
Molecular Cancer Therapeutics. 16:516-528
Patients with metastatic uveal melanoma usually die within 1 year of diagnosis, emphasizing an urgent need to develop new treatment strategies. The liver is the most common site of metastasis. Mitogen-activated protein kinase kinase (MEK) inhibitors
Autor:
Bao Quoc Lam, Andrew E. Aplin, Grazia Ambrosini, Takahito Sugase, Vivian Chua, Connie Liao, Marlana Orloff, Mizue Terai, Takami Sato, Gary K. Schwartz, Timothy J. Purwin, Jessica L.F. Teh, Richard D. Carvajal
Publikováno v:
EMBO Molecular Medicine
EMBO Molecular Medicine, Vol 11, Iss 2, Pp n/a-n/a (2019)
EMBO Molecular Medicine, Vol 11, Iss 2, Pp n/a-n/a (2019)
Alterations in transcriptional programs promote tumor development and progression and are targetable by bromodomain and extraterminal (BET) protein inhibitors. However, in a multi‐site clinical trial testing the novel BET inhibitor, PLX51107, in so